Insights

Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.

Tagged biosimilar · clear

Top 10 Pharmaceuticals Losing Exclusivity in the US in 2024

As the relentless march of time continues, pharmaceutical executives find themselves facing the inevitability of patent expirations and the subsequent entry of generic or biosimilar competition. This reality underscores the imperative for continual…

March 11, 2024Pharma & ANDA2 min read

Pharma & ANDA

Patexia Insight 157: Most Active Companies in Biosimilar Litigation (BPCIA Act)

In late August, we published our third annual ANDA Litigation Intelligence Report. We evaluated the stakeholders for Hatch-Waxman cases filed between July 1, 2017, and June 30, 2022. This report's major highlights have been covered in our previous…

November 3, 2022Pharma & ANDA8 min read